KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBIT Margin (2019 - 2025)

Historic EBIT Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 11.41%.

  • Esperion Therapeutics' EBIT Margin rose 196300.0% to 11.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.67%, marking a year-over-year decrease of 152400.0%. This contributed to the annual value of 16.37% for FY2024, which is 1500900.0% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' EBIT Margin is 11.41%, which was up 196300.0% from 8.61% recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' EBIT Margin peaked at 52.47% during Q1 2024, and registered a low of 1038.15% during Q1 2021.
  • Over the past 5 years, Esperion Therapeutics' median EBIT Margin value was 131.37% (recorded in 2023), while the average stood at 178.52%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 30078200bps in 2021, then plummeted by -1979800bps in 2022.
  • Quarter analysis of 5 years shows Esperion Therapeutics' EBIT Margin stood at 361.2% in 2021, then skyrocketed by 37bps to 225.92% in 2022, then soared by 42bps to 131.37% in 2023, then surged by 95bps to 6.4% in 2024, then tumbled by -78bps to 11.41% in 2025.
  • Its last three reported values are 11.41% in Q3 2025, 8.61% for Q2 2025, and 34.0% during Q1 2025.